Running title: LPL mobility in the interstitial spaces Abbreviations: GPIHBP1, glycosylphosphatidylinositol-anchored high density lipoprotein binding protein 1; TRLs, triglyceride-rich lipoproteins; HSPGs, heparan sulfate proteoglycans; DAPI, 4',6-diamidino-2-phenylindole. 
INTRODUCTION
Lipoprotein lipase (LPL), a triglyceride hydrolase that is synthesized and secreted by myocytes and adipocytes, is crucial for the lipolytic processing of triglyceride-rich lipoproteins (TRLs) inside blood vessels (1) (2) (3) . For decades, dogma held that the LPL produced by myocytes and adipocytes was bound to negatively charged heparan-sulfate proteoglycans (HSPGs) in the glycocalyx coating of blood vessels (4) .
This model was plausible because LPL contains positively charged heparin-binding domains (5) (6) (7) (8) , and LPL binds avidly to HSPGs on cultured cells and to HSPGs immobilized on 96-well plates (9). Moreover, LPL was known to be released into the plasma with an injection of heparin (1, 2) . Over the past 8 years, however, this model for intravascular lipolysis has changed. We now recognize that GPIHBP1, a GPIanchored protein of capillary endothelial cells, is the binding site for LPL (10) . GPIHBP1 captures LPL within the interstitial spaces and shuttles it across endothelial cells to the capillary lumen (10, 11) . The GPIHBP1-LPL complex on the surface of capillaries is also crucial for the margination of TRLs along capillaries, making it possible for LPL-mediated TRL processing to proceed (12) . GPIHBP1 expression is required for TRL processing (11) . Several mutations in GPIHBP1's cysteinerich Ly6 domain have been identified in patients with severe hypertriglyceridemia ("familial chylomicronemia syndrome") (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) . All of those mutations block the ability of GPIHBP1 to bind and transport LPL. Recent surface plasmon resonance studies have indicated that GPIHBP1's Ly6 domain is primarily responsible for high-affinity LPL binding, while the acidic domain at GPIHBP1's amino terminus simply promotes the formation of an initial LPL-GPIHBP1 complex (23, 24) .
Immunohistochemistry studies on wild-type and GPIHBP1-deficient mice (Gpihbp1 -/-) have provided key insights into LPL and GPIHBP1 physiology. In wild-type mice, the vast majority of the LPL in sections of heart is bound to GPIHBP1 on capillaries (10) , revealing that freshly secreted LPL can move efficiently to endothelial cells. The LPL in wild-type mice can be released into the plasma with an injection of heparin (25) . The immunohistochemistry studies on heart sections from Gpihbp1 -/-mice were arguably more intriguing. In the absence of GPIHBP1, the LPL remained attached to HSPGs on the surface of all cells within the tissue. As in wild-type mice, the LPL in Gpihbp1 -/-mice could be released by guest, on www.jlr.org
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Christopher M. Allan et al. Page 4 of 4 into the plasma with an injection of heparin (10, 25) . Thus, in the absence of GPIHBP1, the LPL remains bound to HSPGs within the interstitial spaces; that HSPG-bound LPL, which is catalytically active (25) , does not simply diffuse away into the lymph and reach the plasma. Indeed, the levels of LPL in the plasma of Gpihbp1 -/-mice are far lower than in wild-type mice, implying that the binding of LPL to interstitial HSPGs is quite avid and efficient.
The fact that the LPL in Gpihbp1 -/-mice accumulates in the interstitium, mainly on the surface of cells, and does not enter the plasma compartment poses a conundrum: Why don't the same interstitial HSPG binding sites in wild-type mice capture newly secreted LPL and thereby impede the movement of LPL to endothelial cells? The answer to that question is not known, but we hypothesize that the binding of LPL to interstitial HSPGs is actually dynamic (with high "on" and "off" rates), such that the LPL is constantly bouncing on and off a large pool of HSPG binding sites. Such a scenario would explain how LPL can move to high-affinity GPIHBP1 binding sites on capillaries. In the current study, we tested, using both cell culture and mouse models, the concept that the binding of LPL to HSPGs is dynamic and transient, allowing for rapid transfer of LPL to GPIHBP1.
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MATERIALS AND METHODS
Immunohistochemistry on the mouse mammary gland
Mammary glands were harvested from lactating wild-type and Gpihbp1 -/-mice. Frozen sections (8) (9) (10) µm) were incubated with primary antibodies [3 µ g/ml for monoclonal antibody 11A12; 1:400 for a hamster anti-CD31 antibody (Millipore, Billerica, Mass); 1:1000 for a rabbit anti-collagen type IV antibody (Cosmo Bio USA, Carlsbad, CA); 10 µg/ml for a goat anti-mouse LPL antibody]. Secondary antibodies (Alexa555-or Alexa647-labeled anti-rat IgG, Alexa488-or Alexa647-labeled anti-hamster IgG, Alexa488-or Alexa647-labeled anti-rabbit IgG, and Alexa549-or Alexa488-labeled anti-goat IgG)
were used at a dilution of 1:200 for 1 h at room temperature. Images were obtained with an Axiovert 200
MOT microscope equipped with an Apotome (both from Zeiss, Germany) or by confocal fluorescence microscopy with a Leica SP2 1P-FCS microscope (Heidelberg, Germany).
Western blots
Proteins were size-fractionated on 12% NuPAGE SDS-PAGE gels with MES buffer, followed by transfer to a nitrocellulose membrane. The nitrocellulose membranes were blocked for 1 h at room temperature with Odyssey Blocking Buffer (LI-COR) and then incubated with a goat polyclonal antibody against mouse LPL (10 µg/ml) (26) followed by an IRDye800-conjugated donkey anti-goat IgG (LI-COR); a mouse monoclonal antibody against the V5 tag (ThermoFisher Scientific; 1:500) followed by an IRDye800-conjugated donkey anti-mouse IgG (LI-COR); a goat polyclonal antibody against the S-protein tag (Abcam; 1:1000) followed by an IRDye680-conjugated donkey anti-goat IgG (LI-COR); a rabbit polyclonal antibody against β -actin (Novus Biologicals; 1:1000) followed by an IRDye800-conjugated donkey anti-rabbit IgG (LI-COR); and antibody 11A12 (3 µg/ml) followed by an IRDye680-conjugated donkey anti-rat IgG). Signals were visualized with an Odyssey scanner (LI-COR).
Release of tissue-associated LPL by heparinase III
Gpihbp1 -/-mice were sacrificed and perfused with PBS. The interscapular brown adipose tissue and heart were harvested and embedded in OCT medium on dry ice. Tissue sections of the heart (7 µm) and brown by guest, on www.jlr.org Downloaded from adipose tissue (10 µm) were prepared and placed on glass slides. Tissue sections were then incubated for 1 h at room temperature with PBS alone or PBS containing 10 U/ml of heparinase III (Sigma-Aldrich).
The solution was collected and analyzed by western blotting.
Preparation of soluble human GPIHBP1
We produced secreted versions of human wild-type GPIHBP1, GPIHBP1-W109S, and GPIHBP1Δ in Drosophila S2 cells (27) . These GPIHBP1 proteins contained a uPAR tag (27) and the epitope for the GPIHBP1-specific monoclonal antibody 11A12 (28) . The GPIHBP1 proteins were purified over agarose beads coated with the uPAR-specific monoclonal antibody R24 (29). containing 50 units of heparin/ml, 2 mg of triglyceride/ml in PBS/Mg/Ca containing 6% BSA (w/v) pH 7.4, and 5% (v/v) heat-inactivated rat serum (as a source of apo-CII). Samples were incubated at room temperature for 90 min, followed by lipid extraction and scintillation counting (32) .
Testing the ability of HSPG-bound LPL on HepG2 cells to move to GPIHBP1-loaded agarose beads
We tested the movement of LPL from V5-LPL-loaded HepG2 cells to agarose beads harboring recombinant human GPIHBP1. To prepare GPIHBP1-agarose beads, we added 8.5 µg GPIHBP1 proteins
[wild-type GPIHBP1, GPIHBP1-W109S, or GPIHBP1Δ(25-50)] or buffer alone to 100 µl antibody 11A12-coated agarose beads (33). The agarose beads were then placed adjacent to the coverslips containing V5-LPL-loaded HepG2 cells in 6-well plates and incubated for 2 h at 4°C. The beads (spatially separated from the coverslips) were then collected and washed, and any LPL that had moved to GPIHBP1 on the surface of the beads was eluted with SDS sample buffer (10 min at 90°C). The amounts of GPIHBP1 and LPL were analyzed by western blotting.
Testing the ability of GPIHBP1 to capture LPL from HSPGs in tissues of Gpihbp1 -/-mice
Antibody 11A12-coated agarose beads that had been incubated with wild-type GPIHBP1 (or buffer alone) were injected into the interscapular brown adipose tissue of wild-type or Gpihbp1 -/-mice (50 µl of agarose beads containing 6.5 µg GPIHBP1 injected into each pad). After 45 min, the mice were sacrificed and perfused with PBS followed by 3% paraformaldehyde. The brown adipose tissue pad was then harvested and embedded in OCT medium on dry ice. Tissue sections (10 µm) were fixed with methanol at -20ºC for 10 min, permeabilized with 0.2% Triton X-100 for 5 min, and blocked at room temperature with 5% donkey serum, 10% fetal bovine serum, and 0.2% BSA in PBS/Mg/Ca. Tissues were incubated overnight at 4°C with a goat polyclonal antibody against mouse LPL (7 µg/ml) (26) 
RESULTS
Mislocalization of LPL in the mammary gland of Gpihbp1 -/-mice
Davies et al. (10) reported that LPL in the heart of Gpihbp1 -/-mice is mislocalized, with most of it located on or near the surface of cells (both cardiomyocytes and endothelial cells). We wanted to determine if the LPL in Gpihbp1 -/-mice was also mislocalized in the lactating mammary gland, a site with high levels of LPL expression (34) . In wild-type mice, most of the LPL in the mammary gland was bound to capillaries, co-localizing with the endothelial cell marker CD31 (Fig. 1A-B) . In Gpihbp1 -/-mice, LPL did not colocalize with CD31 and instead was mislocalized in the interstitial spaces on or near mammary epithelial cells (Fig. 1C) .
We have assumed that the LPL within the interstitial spaces of Gpihbp1 -/-mice was bound to HSPGs because the LPL in those mice was readily released into the plasma with an injection of heparin (25) . To test that idea, we treated heart and brown adipose tissue sections from Gpihbp1 -/-mice with heparinase III, an enzyme that cleaves heparan sulfates. As we had predicted, that treatment released LPL from sections of both heart and brown adipose tissue (Supplemental Figure S1 ).
Testing the ability of soluble GPIHBP1 to capture LPL from the surface of HepG2 cells
We loaded the surface of HepG2 cells, which are known to be rich in cell-surface HSPGs (31), with V5-tagged human LPL. As expected, the LPL on the surface of those cells could be released with heparinase III (Supplemental Figure S2) . To determine if soluble GPIHBP1 (GPIHBP1 lacking the GPI anchor)
would capture LPL from HSPGs on HepG2 cells, we added soluble GPIHBP1 to the medium of HepG2 cells that had been preloaded with V5-LPL. We then assessed the amount of LPL that was released into the medium and the amount of LPL remaining on the surface of the cells. With increasing amounts of GPIHBP1 in the medium, more LPL was released into the medium and less remained attached to HepG2 cells ( Fig. 2A) . We also showed that the release of LPL by recombinant GPIHBP1 increased steadily between 5 and 30 min (Fig. 2B) . Interestingly, a small amount of LPL was released from cells during a 30-min incubation with buffer alone, but the amount released with buffer was less than the amount released during a 5-min incubation with GPIHBP1 (Fig. 2B) . (Fig. 3A-B) . We performed similar studies in which the HepG2 cells were loaded with bovine LPL. In those studies, we assessed the movement of bovine LPL to transfected CHO pgsA-745 cells by measuring the activity of LPL on the surface of the CHO cells. The cells expressing wild-type GPIHBP1 and the acidic domain mutant captured catalytically active bovine LPL from the HSPG-bound pool on HepG2 cells (Fig. 3C) .
The movement of LPL from HepG2 cells to cells expressing wild-type GPIHBP1 and the acidic domain mutant was evident by immunocytochemistry (Fig. 3D) . LPL did not move to cells expressing GPIHBP1-W109S. As an additional control, we tested the ability of GPIHBP1-bound LPL to move from GPIHBP1-expressing CHO pgsA-745 cells to HepG2 cells. As expected, movement of LPL from GPIHBP1 to HSPGs on HepG2 cells was not detectable (Supplemental Figure S4) .
Assessing the movement of HSPG-bound LPL to GPIHBP1-loaded agarose beads
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Christopher M. Allan et al. Page 12 of 12 The experiments in Figure 2 revealed that soluble GPIHBP1 in the medium captures the LPL that is spontaneously released from HepG2 HSPGs, but the next goal was to determine whether GPIHBP1 was also effective in capturing LPL when GPIHBP1 is spatially separated from the cells. To address this issue, we captured soluble GPIHBP1 on agarose beads coated with the GPIHBP1-specific monoclonal antibody 11A12, and then placed the agarose beads in 6-well plates adjacent to the coverslips containing LPL-loaded HepG2 cells. We then recovered beads that were spatially separated from the coverslips.
Even though the beads were not in contact with the HepG2 cells, the LPL nevertheless diffused away from HSPGs on HepG2 cells and was captured/concentrated on agarose beads coated with wild-type GPIHBP1 or the acidic domain GPIHBP1 mutant (where the release was 87.9% of the amount released with wild-type GPIHBP1). We observed far lower migration of LPL to agarose beads coated with GPIHBP1-W109S (Fig. 4) .
Testing the mobility of HSPG-bound LPL in Gpihbp1 -/-mouse tissue to GPIHBP1 on agarose beads
We next tested whether LPL would move from HSPGs in tissues of Gpihbp1 -/-mice to GPIHBP1-loaded agarose beads in vivo. For this purpose, we injected GPIHBP1-loaded agarose beads (or simply 11A12-coated beads) into the interscapular brown adipose tissue of wild-type or Gpihbp1 -/-mice. Thousands of beads were injected. After 45 min, the brown adipose tissue was harvested and processed for immunohistochemistry. In the absence of any bead injection, the LPL in brown adipose of Gpihbp1 -/-mice was mislocalized to the interstitial spaces, whereas the LPL in the brown adipose tissue of wild-type mice was associated with capillaries (colocalizing with CD31) (Fig. 5, Supplemental Figure S5 ). In Gpihbp1 -/-brown adipose tissue that was injected with the GPIHBP1-loaded beads, the interstitial LPL moved to the beads, and that movement was accompanied (in three independent experiments) by reduced LPL staining within the interstitium of the brown adipose tissue (Fig. 5, Supplemental Figure S5 ). In
Gpihbp1 -/-brown adipose tissue injected with 11A12-coated beads (i.e., no GPIHBP1), the LPL did not move to the beads, and there was no detectable depletion of LPL in the interstitium (Fig. 5) . In wild-type mice, we expected that some freshly secreted LPL would be captured by GPIHBP1-coated agarose beads.
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Indeed, movement of LPL to GPIHBP1-loaded agarose beads was also observed in brown adipose tissue of wild-type mice (Fig. 5, Supplemental Figure S5 ). HSPGs on or near the surface of these cells. The ability of interstitial HSPGs to capture LPL is obviously robust, given that levels of LPL in the plasma are lower in Gpihbp1 -/-mice than in wild-type mice (25) .
Given the robust binding of LPL to the interstitial HSPGs in Gpihbp1 -/-mice, we did not understand why the LPL in wild-type mice would not be captured by the same interstitial HSPGs, thereby limiting the ability of LPL to move to capillaries. The most straightforward explanation for this conundrum is that the HSPG-bound LPL in the interstitium is highly mobile. In the past, others had shown that the binding of fibroblast growth factor (FGF) to HSPGs is avid, but that the "off-rate" of FGF from HSPGs is high (35) .
Biacore experiments have suggested that the off-rate of LPL from HSPGs is also high (36, 37) , raising the possibility that the LPL in the interstitial spaces of wild-type mice would be capable of "moving past" the HSPG binding sites. Our current studies support this concept. We found that LPL, when bound to HSPGs on the surface of HepG2 cells, moved within minutes to: (1) soluble GPIHBP1 in the medium; (2) GPIHBP1 on the surface of GPIHBP1-transfected cells; and (3) GPIHBP1 on the surface of nearby agarose beads. Thus, it is clear that LPL readily detaches from HSPG binding sites, allowing it to move to higher affinity binding sites, namely GPIHBP1 on endothelial cells. An obvious limitation of these cell culture studies, however, is that we had no way of knowing whether the behavior of HSPG-bound LPL on
HepG2 cells is relevant to the binding of LPL to the interstitial HSPGs in vivo.
To be confident that our cell culture findings were physiologically relevant, we captured GPIHBP1 on antibody 11A12-coated beads and then injected those beads into the interscapular brown adipose tissue of Gpihbp1 -/-mice. Our goal was to determine, by immunohistochemistry, whether any of the LPL that is by guest, on October 14, 2017
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bound to interstitial HSPGs in Gpihbp1 -/-mice would be capable of moving to the GPIHBP1-coated beads. The results from these studies were clear and consistent: within 45 min, the LPL in brown adipose tissue moved to GPIHBP1-coated beads, and the LPL stores in the interstitial spaces fell. In contrast, LPL did not move to agarose beads coated with mAb 11A12 alone. Thus, "bound LPL" within the interstitial spaces can move to GPIHBP1. LPL also moved to GPIHBP1-agarose beads in the brown adipose tissue of wild-type mice. We did not consider the latter result surprising, simply because the amount of GPIHBP1 on the surface of the beads was very substantial (>5 µg/injection) and there was no reason to believe that it would lack the capacity to bind freshly secreted LPL.
In our studies, we observed little or no movement of HSPG-bound LPL to a mutant GPIHBP1
harboring an amino acid substitution in GPIHBP1's Ly6 domain (W109S), whereas there was substantial movement of HSPG-bound LPL to "acidic domain GPIHBP1 mutants" (i.e., GPIHBP1 that lacked the acidic domain or GPIHBP1 in which the Asp and Glu residues in the acidic domain had been replaced with Asn or Gln). We chose to test GPIHBP1-W109S because earlier studies had revealed that that mutation virtually eliminates the binding of LPL to GPIHBP1 and does so without causing inappropriate intermolecular disulfide bond formation and protein multimerization (27) . The discovery that GPIHBP1
lacking the acidic domain is capable of capturing LPL from HSPGs is consistent with recent findings by Mysling and coworkers (24) . Using purified proteins and surface plasmon resonance experiments, they showed that GPIHBP1's Ly6 domain is primarily responsible for high-affinity LPL-GPIHBP1
interactions. Early and less refined LPL-GPIHBP1 binding assays had suggested that GPIHBP1's acidic domain was important for LPL binding (38) , but the surface plasmon resonance studies by Mysling et al. Another study using surface plasmon resonance (37) reported that the affinity of LPL binding was greater for GPIHBP1's Ly6 domain than for heparan sulfate. In these studies, the on-rates for LPL binding to GPIHBP1 and heparan sulfate were similar, but the off-rate was far greater with heparan sulfate. These measurements support our experimental results showing that LPL readily moves from HSPGs to GPIHBP1.
Our studies suggest a framework for understanding LPL physiology within tissues.
Immunohistochemistry studies on sections of Gpihbp1 -/-tissues appear to show tight binding of LPL within the interstitial spaces, but our current studies indicate that the seemingly tight binding of LPL to
HSPGs is actually dynamic-explaining how LPL in wild-type mice can "move past" HSPGs to GPIHBP1 on capillary endothelial cells. We believe that the duality of LPL binding sites in tissues 
